Organizations: Stanford University · HKUST (Guangzhou) · Amazon · SJTU · University of Chicago · University of Notre Dame · HKUST · Nanjing University · CISPA · CUHK · Yale University · Universität Hamburg · Lexicodon
Protein-protein interactions underpin nearly all biological processes. Yet, designing proteins with desired interactions remains challenging due to the structural complexity governing molecular recognition. This study views protein design as a search optimization problem over a combinatorial sequence space under expensive structural evaluation. Toward this goal, we introduce a novel tree-based search framework, ProteoCraft, that employs approximate structural gradients from diffusion-based structure predictors as effective proposal policies to specify where the search should explore. Complete no-gradient inference of folding models separately assigns values to the resulting sequences, determining what is good. ProteoCraft allocates this verification budget through a coarse-to-fine paradigm: multi-site edits first explore distinct sequence basins, then verified promising states undergo strict single-site refinement. Across fourteen de novo binder-design settings spanning eight target proteins, five immune-relevant TCR-facing targets, and four localized CDR redesign tasks, ProteoCraft improves design quality and high-confidence yield. These improvements persist under independent AF2-IG and Rosetta-based interface evaluation. Prospective experimental validation further yielded an 82.9% binding hit rate for PD-L1 miniproteins, with a best measured KD of 0.879 nM, and confirmed binding of designed IFNAR2 VHH. Our code is available at https://github.com/smiles724/ProteoCraft_v1.
Figures & tables
Figure 1: Design quality versus computational cost.
Figure 2: Overview. ProteoCraft formulates protein design as proposal–verification search. Given a mutable design region and molecular context, a coarse-to-fine tree search uses truncated diffusion signals to propose candidate sequences, while complete ESMFold2 inference assigns node values.
Method
Mean confidence ↑
High-confidence yield ↑
Pair iPTM
iPTM
pTM
pLDDT
Binder pLDDT
Pair iPTM ≥0.5
Pair iPTM ≥0.7
Pair iPTM ≥0.75 Binder pLDDT ≥0.9
RFdiffusion v3
0.206
0.282
0.593
0.739
0.729
20 (9.5%)
1 (0.5%)
0 (0.0%)
BoltzGen
0.438
0.577
0.748
0.826
0.857
105 (50.0%)
45 (21.4%)
9 (4.3%)
Proteina-Complexa
0.286
0.386
0.653
0.774
0.779
48 (22.9%)
4 (1.9%)
0 (0.0%)
PXDesign-d
0.322
0.433
0.683
0.801
0.832
58 (27.6%)
16 (7.6%)
1 (0.5%)
BoltzDesign1
0.154
0.220
0.562
0.638
0.490
6 (2.9%)
0 (0.0%)
0 (0.0%)
Table 1: ESMFold2 evaluation of de novo binder design on 14 target–hotspot settings across eight target proteins. Each method contributes 15 candidates per hotspot ( N=210 ). The left block reports mean confidence metrics (higher is better); the right block reports high-confidence design yields as count (percentage). The strict criterion requires both Pair iPTM ≥0.75 and Binder pLDDT ≥0.9 . Dashes indicate results not yet reported.
AF2-IG
Rosetta interface evaluation
Method
iPAE ↓
iPTM ↑
pTM ↑
Strict Pass ↑
ΔG↓
ΔSASA↑
SC ↑
ΔG/ΔSASA↓
H-bonds ↑
Packstat ↑
RFdiffusion v3
25.426
0.142
0.550
0 (0.0%)
-49.398
1834.2
0.633
-2.696
4.662
0.612
BoltzGen
26.342
0.200
0.689
0 (0.0%)
-31.138
1902.4
0.558
-1.640
6.463
0.654
Proteina-Complexa
18.927
0.359
0.651
6 (2.9%)
-28.741
1626.0
0.557
-1.671
5.314
0.597
PXDesign-d
18.949
0.349
0.650
20 (9.5%)
-50.477
2029.6
0.603
-2.469
8.595
0.597
BoltzDesign1
19.967
0.369
0.571
1 (0.5%)
-52.903
3251.0
0.607
-1.611
7.743
0.542
Table 2: Independent AF2-IG and Rosetta evaluation of de novo designs. Each was evaluated on N=210 designs. For AF2-IG, lower iPAE and higher iPTM, pTM, and strict pass rate are better. For Rosetta, lower ΔG and ΔG/ΔSASA and higher values for the remaining metrics are better. Bold and underlined values indicate the best and second-best results, respectively.
ESMFold2
AF2-IG
Method
Pair iPTM ↑
iPTM ↑
pTM ↑
pLDDT ↑
iPAE ↓
iPTM ↑
pTM ↑
RFdiffusion v3
0.225
0.695
0.780
0.852
27.540
0.161
0.693
BoltzGen
0.384
0.763
0.824
0.843
26.342
0.200
0.689
Proteina-Complexa
0.300
0.756
0.822
0.863
26.439
0.191
0.702
PXDesign-d
0.276
0.717
0.795
0.873
26.115
0.207
0.708
BoltzDesign1
0.228
0.734
0.810
0.817
26.165
0.214
0.713
Table 3: TCR-facing binder design. The left block reports complete ESMFold2 verification and the right block reports independent AF2-IG evaluation.
Method
Case
N
Peptide Pair ↑
Mean Pair ↑
iPTM ↑
pTM ↑
Complex pLDDT ↑
Chain pLDDT ↑
RFdiffusion v3
1QRN α
10
0.591
0.686
0.872
0.896
0.919
0.901
1QRN β
10
0.421
0.560
0.824
0.857
0.905
0.912
9NMW α
10
0.549
0.669
0.884
0.900
0.906
0.896
9NMW β
10
0.579
0.687
0.909
0.920
0.914
0.918
Mean
–
0.535
0.650
0.872
0.893
0.911
0.907
BoltzGen
1QRN α
10
0.715
0.761
0.926
0.934
0.929
0.912
Table 4: ESMFold2 evaluation for localized CDR redesign. Peptide Pair iPTM measures confidence between the redesigned chain and the peptide; Mean Pair iPTM averages pairwise confidence between the redesigned chain and all fixed context chains. All metrics are higher-is-better.
AF2-IG
Rosetta
Method
iPAE ↓
iPTM ↑
pTM ↑
pLDDT ↑
ΔG↓
SC ↑
H-bonds ↑
Packstat ↑
RFdiffusion v3
17.483
0.505
0.665
0.871
-103.9
0.681
14.200
0.488
BindCraft
23.294
0.360
0.602
0.642
-78.3
0.571
14.750
0.618
ProteoCraft-MCTS
14.558
0.753
0.716
0.851
-138.3
0.702
24.575
0.673
Table 5: Independent cross-evaluation of localized CDR redesign.
Figure 3: Wet-lab validation of ProteoCraft-designed binders. Complex structures and biolayer interferometry sensorgrams for the selected de novo binders against PD-L1 (left) and IFNAR2 (right).
Figure 4: Accelerating ProteoCraft through inference optimization.
Method
De novo
TCR
PXDesign-d
18.72
21.01
Proteina-Complexa
14.62
34.61
RFdiffusion v3
56.64
44.26
BoltzDesign1
693.38
2882.20
BindCraft v2
2321.50
—
ProteoCraft
32.34
174.06
Table 6: Runtime comparison. We report mean wall-clock latency (seconds) per binder under each method’s native design and selection procedure. Details are in Appendix C.3 .
Table 8: Hotspot definitions for eight de novo target proteins and five TCR-facing target systems.
PDB / case
TCR target
Antigen / restriction
1QRN
A6 TCR
TAX-A2
3QDJ
DMF5 TCR
MART1-A2
5BS0
A3A TCR
MAGEA3-A1 / Titin-A1
6BJ8
TCR55
HIV-B35
9C3E
1G4 TCR
NYESO-A2
Appendix
Table 9: TCR-facing binder-design systems.
Case
CDR3 sequence
Residue range
9NMW α
CAVNNARLMFGDGTQL
90–105
9NMW β
CASSVAGSPEAFF
89–101
1QRN α
CAVTTDSWGKLQF
88–100
1QRN β
CASRPGLAGGRPEQYF
91–106
Appendix
Table 10: Localized CDR redesign settings.
Target
PXDesign-d
RFdiffusion v3
BoltzDesign1
No One-step
Base / Best-of- N
ProteoCraft-MCTS
BetV1
0.257
0.185
0.087
0.793
0.725
0.832
DerF21-B10
0.462
0.241
0.214
0.698
0.746
0.771
DerF21-B28
0.449
0.170
0.099
0.630
0.729
0.770
DerF21-B63
0.378
0.206
0.140
0.699
0.738
0.787
DerF21-B81
0.392
0.140
0.178
0.600
0.725
0.756
DerF21-B92
0.340
0.194
0.219
0.716
0.695
0.746
Appendix
Table 11: Mean ESMFold2 Pair-chain iPTM across the 15 candidates for each matched de novo target. Higher is better.
Case
Total Length
PXDesign-d
RFdiffusion3
Complexa BoN+AF2
BoltzDesign1
BindCraft v2
ProteoCraft
De novo binder design
IFNAR2
199
13.53
49.21
14.28
458
512
11.62
PD-L1
208
14.13
49.40
14.10
504
303
13.54
PD1
220
16.40
63.64
12.05
505
1128
14.96
DerF21
257
11.49
56.46
15.05
522
253
17.17
BetV1
261
14.40
48.17
16.05
686
11523
19.76
Appendix
Table 12: Runtime comparison across different targets, reported in seconds per binder. Averages are computed separately over eight de novo and five TCR cases. Besides, — indicates no filter-passing designs within the TCR sampling budget for BindCraft v2.
Figure 5: Design quality with accelerated ESMFold2 inference.
τ
Pair iPTM ↑
iPTM ↑
pTM ↑
pLDDT ↑
1
0.682
0.871
0.896
0.886
2
0.777
0.930
0.939
0.921
4
0.730
0.914
0.931
0.909
Appendix
Table 13: Sensitivity to the one-step diffusion noise level. All settings use the same three targets and matched search configuration.